This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Undifferentiated schizophrenia미분화조현병 (미분화형정신분열증)

📋 Contents and key points
ItemDetails
A. Classification codesICD-10: F20.3 (Undifferentiated schizophrenia) | Special Copayment Reduction: V161 (severe intractable disease, copayment reduction for 5 years after registration)
B. Synonymsundifferentiated schizophrenia, atypical schizophrenia
C. Adult onsetPossible first onset in adulthood — the age-of-onset distribution of undifferentiated schizophrenia is broader than other subtypes, with onset from adolescence to early adulthood (ages 15–35). It is often diagnosed as the undifferentiated type at first onset because of a complex picture meeting criteria of several subtypes.
1. HistoryRecognized as a 'residual group' not corresponding to a clear subtype in early classification → made an independent undifferentiated subtype in ICD-10 and DSM-IV → subtypes abolished in DSM-5 and integrated into a single schizophrenia diagnosis.
2. CausesShares the common causes of schizophrenia in general (genetic vulnerability, neurodevelopmental abnormality, dopamine and glutamate abnormalities); characteristics of a single subtype are not prominent, so complex etiologies are involved.
3. GeneticsCommon polygenic risk of schizophrenia; subtype-specific genetic findings not established; when diagnosed as the undifferentiated type at the first-episode psychosis stage, distributed across PGC risk loci overall.
4. General epidemiologyAccounts for about 15~25% of all schizophrenia; high proportion of the undifferentiated type in first-episode psychosis owing to diagnostic uncertainty or mixed symptoms; tendency for subtype shift over time (especially converging on the paranoid type).
5. PathophysiologyCommon mechanisms of schizophrenia (mesolimbic dopamine hyperactivity, reduced NMDA function, GABA interneuron abnormality) are involved in combination, with no distinct neurobiological characteristic of a single subtype.
6. SymptomsMixture of positive symptoms (delusions, auditory hallucinations), negative symptoms, and disorganization symptoms; does not meet the criteria of any single subtype (paranoid, hebephrenic, catatonic) alone, or meets the criteria of multiple subtypes at the same time.
7. SignsMixed symptom pattern on mental status examination; delusions, auditory hallucinations, disorganization, and negative symptoms appear in various combinations; a distribution of moderate scores on all 5 PANSS factors is typical.
8. ScreeningMultidimensional assessment integrating PANSS, BPRS, CDSS (depression), and MCCB (cognition); screening system within first-episode psychosis early intervention programs.
9. DiagnosisICD-10 F20.3: general criteria for schizophrenia are met but the criteria for paranoid, hebephrenic, catatonic, post-schizophrenic depression, and residual types are not met; the diagnosis must be confirmed only after a sufficient observation period.
10. TreatmentSecond-generation antipsychotic drugs as first-line treatment; drug selection according to symptom profile (proportion of positive, negative, and cognitive symptoms); combined psychosocial treatment and rehabilitation.
11. PrognosisPrognosis is intermediate between the paranoid and hebephrenic types; subtype shift after the first episode is common, and the prognosis tends to follow the characteristics of the subtype shifted to.
12. PreventionEarly intervention and shortening of DUP; achieving first-episode remission with sufficient acute-phase treatment; relapse-prevention maintenance drug therapy and psychosocial support.
13. ReferencesKahn RS, Sommer IE, Murray RM, et al. Schizophrenia. Nat Rev Dis Primers. 2015 … and 9 other papers

1. History

Undifferentiated schizophrenia has served in the history of schizophrenia classification as a 'residual category' created to accommodate patients who do not fit clear subtype criteria. The history of this subtype should be understood together with the development of the schizophrenia classification system.

In the early classifications of Emil Kraepelin and Eugen Bleuler, three subtypes, paranoid, hebephrenic, and catatonic, were mainly described, but in clinical reality a considerable number of patients did not clearly fit these subtypes. Reflecting this clinical reality, the undifferentiated type was first formally included as a subtype in DSM-III (1980). The undifferentiated type in DSM-III corresponded to cases meeting the criteria of two or more subtypes, or meeting the criteria of none.

ICD-10 (1992) classified undifferentiated schizophrenia as F20.3. The ICD-10 criteria for the undifferentiated type include cases that meet the general criteria for schizophrenia but do not satisfy the criteria for F20.0 (paranoid), F20.1 (hebephrenic), or F20.2 (catatonic), or that satisfy all of those criteria. DSM-IV (1994) also defined the undifferentiated type in a similar way.

The undifferentiated type is also an important code reflecting diagnostic uncertainty in clinical practice. In patients with first-episode psychosis, it is often difficult to settle on a specific subtype without a sufficient observation period, so provisional diagnosis as the undifferentiated type followed by observation of the course is common. In this sense, the undifferentiated type also has the character of 'a stage in the diagnostic process'.

When schizophrenia subtypes were abolished entirely in DSM-5 in 2013, the undifferentiated type was also removed from the official categories. DSM-5 integrated schizophrenia into a single diagnosis and shifted to assessment along symptom dimensions (positive, negative, cognitive, depressive, manic, psychomotor). One of the reasons for this change was that the fact that the undifferentiated type was the most frequently used subtype code paradoxically showed the limits of the subtype classification system itself. In contrast, ICD-10 and ICD-11 retained the undifferentiated type code, so F20.3 continues to be used in Korean clinical practice.


2. Causes

The cause of undifferentiated schizophrenia is understood in the same framework as the vulnerability-stress model applied to schizophrenia in general. The clinical characteristic that the features of no single subtype are prominent reflects either that multiple etiological factors are involved in combination, or that the subtype features have not yet sufficiently crystallized early in the illness.

Genetic vulnerability: The polygenic risk structure of schizophrenia applies equally to the undifferentiated type. Heritability is similar to that of schizophrenia overall (about 60~80%), and subtype-specific genetic patterns have not been established. When there is a family history, even if the first episode appears as the undifferentiated type, it often converges on a specific subtype later.

Neurodevelopmental abnormality: When fetal and early neurodevelopmental disturbance affects various neural circuits unevenly, so that multiple circuits show mild abnormalities rather than one circuit being prominently damaged, the clinical picture of the undifferentiated type may appear. From this viewpoint, the undifferentiated type is likely to be an etiologically heterogeneous group.

Neurochemical factors: When abnormalities of the dopamine, glutamate, GABA, and serotonin systems coexist, a complex clinical picture in which no single symptom group is prominent may appear. In particular, in first-episode psychosis at a stage when neurochemical abnormalities are not yet fully expressed, it may appear as the undifferentiated type.

Environmental factors: Common environmental risk factors for schizophrenia (urban residence, immigration, cannabis use, traumatic experiences, etc.) also apply to the undifferentiated type. In first episodes caused by acute stress, the symptom picture may be mixed and indistinct.


3. Genetics

Genetic research on undifferentiated schizophrenia is included in studies of schizophrenia as a whole, and subtype-specific genetic studies are very limited. Since the abolition of subtypes in DSM-5, the latest large-scale genetic studies analyze schizophrenia as a whole without subtype distinction, so undifferentiated type-specific genetic findings remain a task for future research.

Polygenic risk structure: The 287 risk loci identified in the PGC 2022 meta-analysis apply in common to the undifferentiated type. In polygenic risk score (PRS) studies, there are reports that the PRS distribution of patients with the undifferentiated type shows no significant difference from the paranoid or hebephrenic types. This suggests that the undifferentiated type is not a separate group in genetic structure.

Subtype shift and genetic stability: A considerable number of patients first diagnosed as the undifferentiated type shift to the paranoid type during the course. This shift is not a change in genetic characteristics but reflects a process in which the symptom pattern has not yet sufficiently crystallized early in the illness and specific subtype features become prominent over time. Genetically, the patient had a predisposition to become paranoid type from the start, but was diagnosed as the undifferentiated type at the initial clinical evaluation.

Immunogenetics: Variants in the MHC region (6p21.3) have the largest effect size among schizophrenia risk loci, and C4 gene variants are associated with abnormal synaptic pruning. These immunogenetic factors span all subtypes, including the undifferentiated type, and subtype-specific associations are not known.


4. General epidemiology

Undifferentiated schizophrenia accounts for a considerably large proportion of all schizophrenia diagnoses and is one of the subtypes most commonly coded, especially at the first-episode psychosis stage.

Prevalence: In countries using the ICD-10 classification system, the undifferentiated type accounts for about 15~25% of all schizophrenia. In some studies, use of the undifferentiated type code tends to increase the greater the diagnostic uncertainty in clinical settings, so the actual prevalence varies with study methods and settings. The proportion diagnosed as the undifferentiated type among first-episode psychosis patients is even higher, reaching about 30~40%.

Age of onset and sex: The age of onset of the undifferentiated type lies between the paranoid type (relatively late) and the hebephrenic type (very early), mainly distributed at ages 15~35. Subtype-specific analyses of sex differences are limited, but a pattern similar to schizophrenia overall (earlier onset in men) is observed.

Epidemiology of subtype shift: About 30~50% of patients diagnosed as the undifferentiated type at first onset have their diagnosis changed to another subtype (mainly paranoid) within 5 years. This is because the symptom pattern has not yet crystallized at the first-episode stage. Conversely, shifts from the paranoid or hebephrenic type to the undifferentiated type are mainly observed after chronicity, at the stage when negative symptoms become prominent.

Epidemiology in Korea: In Korea, the F20.3 code is often used for first-episode and acute-phase schizophrenia patients in whom clear subtype classification is difficult. The proportion of patients with the undifferentiated type code is high in mental health welfare centers and community treatment, which is related to the intensive management of patients at the first-episode stage. Treatment cost reduction benefits are provided through Special Copayment Reduction (V161) registration.


5. Pathophysiology

The pathophysiology of undifferentiated schizophrenia involves the neurobiological mechanisms of schizophrenia in general in a mixed manner, without a specific circuit or neurochemical abnormality being prominent as in a single subtype.

Complex neurochemical abnormalities: Mesolimbic dopamine hyperactivity (contributing to positive symptoms), reduced prefrontal cortical dopamine (contributing to negative symptoms and cognitive deficits), reduced NMDA receptor function (contributing to overall symptoms), and GABA interneuron dysfunction (contributing to disorganization symptoms) act in combination, creating an undifferentiated pattern in which none dominates the clinical picture.

Neural network connectivity abnormalities: In fMRI studies of undifferentiated schizophrenia, frontal-limbic, frontal-parietal, and cortico-subcortical connectivity abnormalities are distributed multidimensionally. This suggests global connectivity abnormality rather than selective damage to a single circuit, and explains why various symptom groups are mixed.

Developmental perspective: The undifferentiated type may especially reflect the neurobiological state early in the illness. There is a developmental perspective that, as a stage before the pathology of schizophrenia becomes more prominent in a specific circuit, subtype features crystallize as specific neural circuit abnormalities deepen over time.

Immunological mechanisms: There are reports that neuroinflammatory markers (IL-6, CRP, microglial activation) are elevated in cases diagnosed as the undifferentiated type in first-episode psychosis. This suggests that the immunological state early in the illness may contribute to the diversity of symptom profiles.


6. Symptoms

The key point of the clinical symptoms of undifferentiated schizophrenia is that the core symptoms of schizophrenia are mixed, without dominantly characterizing any single subtype (paranoid, hebephrenic, catatonic).

Mixture of positive symptoms: Delusions (persecutory, reference, grandiose, etc.) and auditory hallucinations are present, but are often not systematized or persistent as in the paranoid type. The content of the auditory hallucinations is inconsistent, several types of delusions appear at the same time, or the intensity of delusions fluctuates over time.

Accompanying negative symptoms: Flat affect, avolition, alogia, and social withdrawal appear together with positive symptoms. Negative symptoms are more prominent than in the paranoid type, but not as much in the foreground as in the hebephrenic type. The presence of negative symptoms often impairs daily functioning.

Partial disorganization of thought and behavior: Thought organization is not completely broken down, but mild loosening of associations, circumstantiality, and tangential thinking may appear. Behavior is also partially disorganized, making performance of daily tasks difficult or causing intermittent odd behavior.

Partial inclusion of catatonic features: Mild psychomotor abnormalities (episodes of mutism, mild posturing, negativism) may appear in some patients, but the typical symptom group of the catatonic type is not met.

Symptom variability: One feature of the undifferentiated type is great variability of symptoms over time. Positive symptoms may be prominent in the acute phase and negative symptoms in the foreground in the remission phase, or the symptom pattern may differ with each episode. This variability is a major factor that makes subtype classification difficult.


7. Signs

The clinical signs of undifferentiated schizophrenia are characterized by a mixture of various symptom groups on mental status examination. When assessed with the PANSS (Positive and Negative Syndrome Scale), a distribution showing moderate scores on the positive subscale, negative subscale, and general psychopathology subscale is typical.

Appearance and behavior: Self-care is partially reduced, but often not completely broken down as in the hebephrenic type. The patient can cooperate at interview, but intermittent guardedness, delusion-related responses, and emotional abnormalities appear. Odd behavior or speech is observed intermittently.

Thought and speech: Delusional thought content is present but not as logically elaborate as in the paranoid type. Mild loosening of associations or circumstantiality is observed, and often there is no complete speech disorganization as in the hebephrenic type. The degree of formal thought disorder varies with the situation.

Emotional expression: Emotional expression is inappropriate to the situation or blunted, but is not completely congruent with the delusions as in the paranoid type, nor completely inappropriate as in the hebephrenic type. Anxiety and depressive symptoms often accompany.

Cognitive function: Impairment of working memory, processing speed, and executive function is confirmed on neuropsychological testing, but is not as severe overall as in the hebephrenic type. The cognitive profile tends to be inconsistent and variable.


8. Screening

Screening for undifferentiated schizophrenia applies the screening methods for schizophrenia in general, but multidimensional assessment to capture the mixture of symptom profiles is important.

Multidimensional symptom assessment: Profile analysis using the PANSS 5-factor model (positive, negative, cognitive, excitement, emotional) is useful for identifying the mixed symptom pattern of the undifferentiated type. The Brief Psychiatric Rating Scale (BPRS) total score and subdomain scores are also used for a similar purpose.

Longitudinal assessment: Regular longitudinal assessment rather than single-time-point cross-sectional assessment is essential to confirm the stability of the undifferentiated type diagnosis and track subtype shift. Reassessment at 6-month to 1-year intervals after the first episode confirms or revises the diagnosis.

Cognitive function assessment: Assessment of baseline cognitive function with the MCCB (MATRICS Consensus Cognitive Battery) helps in establishing the treatment plan and predicting functional prognosis of the undifferentiated type.

Depressive symptom screening: The CDSS (Calgary Depression Scale for Schizophrenia) is important for assessing depressive symptoms in schizophrenia separately from negative symptoms. It is needed for differentiation from schizoaffective disorder or F20.4 (post-schizophrenic depression) when depressive symptoms accompany the undifferentiated type.


9. Diagnosis

Diagnosis of undifferentiated schizophrenia has the structure of a diagnosis of exclusion. It is applied when the general criteria for schizophrenia are met but the criteria for a specific subtype are not.

ICD-10 F20.3 diagnostic criteria: Both of the following conditions must be met. ① The general criteria for schizophrenia (F20) are met. ② The criteria for paranoid (F20.0), hebephrenic (F20.1), catatonic (F20.2), post-schizophrenic depression (F20.4), residual (F20.5), and simple (F20.6) types are not met. Cases meeting the criteria of two or more of F20.0, F20.1, and F20.2 at the same time are also included in the undifferentiated type.

Differential diagnosis: ① Schizoaffective disorder (F25): schizophrenia symptoms and mood episodes (mania or depression) are met simultaneously for a sufficient period. ② Acute and transient psychotic disorder (F23): onset within 2 weeks with full recovery within 3 months. ③ Substance-induced psychosis: psychosis caused by substance use such as cannabis or stimulants, disappearing after withdrawal. ④ Organic psychosis: psychosis due to physical illness, drugs, or brain lesions is excluded by brain MRI and blood tests.

Temporal requirement for diagnostic confirmation: A sufficient observation period (at least 1~3 months) is needed to confirm the undifferentiated type diagnosis. The clinical standard is to reassess the symptom profile after acute-phase symptoms in first-episode psychosis subside and to confirm or revise the subtype.


10. Treatment

Treatment of undifferentiated schizophrenia follows the evidence-based treatment principles for schizophrenia in general, and an individualized approach is needed according to the patient's symptom profile (proportion of positive, negative, cognitive, and depressive symptoms).

Antipsychotic selection: Second-generation (atypical) antipsychotics are the first choice. For a mixed positive and negative symptom profile, drugs relatively effective for negative symptoms (amisulpride, clozapine, olanzapine) are considered first. In treatment-resistant cases, clozapine shows the broadest range of effect on mixed symptom profiles. LAI is recommended for patients in whom adherence is difficult to maintain.

Symptom-specific adjunctive treatment: When negative symptoms are prominent, cognitive remediation, social skills training, and behavioral activation are combined. When depressive symptoms accompany, addition of an SSRI or selection of an antipsychotic with an antidepressant effect such as aripiprazole or amisulpride is considered.

Psychosocial treatment: Psychosocial treatment including CBT, family psychoeducation, and individual recovery-oriented counseling is combined with antipsychotics. Participation in a first-episode psychosis early intervention program (EIP) is favorable for functional recovery.

Community treatment and rehabilitation: Community treatment through day hospitals, psychiatric rehabilitation facilities, supported employment, and ACT teams is essential for maintaining long-term function. Vocational rehabilitation and educational support are key elements for return to society.


11. Prognosis

The prognosis of undifferentiated schizophrenia is understood to be intermediate between the paranoid type (relatively good) and the hebephrenic type (poor), but subtype shift later is common, so prognosis varies with the course.

Short-term prognosis: Response to acute-phase treatment after first-episode psychosis is relatively good, and about 60~80% of patients achieve acute-phase remission. However, the subsequent relapse rate is high, and about 75% experience relapse within 5 years. The quality of first-episode remission (complete vs. partial remission) is an important predictor of long-term prognosis.

Long-term prognosis and subtype shift: About 30-50% of patients diagnosed with the undifferentiated type shift to a paranoid-type diagnosis within 5 years, and after the shift they follow the prognostic characteristics of the paranoid type. About 20-30% shift to a residual type driven by negative symptoms, in which case the functional prognosis becomes poor. When the subtype remains stably undifferentiated, the prognosis is similar to that of the paranoid type.

Functional recovery: In overall functioning (GAF, PSP), patients with the undifferentiated type tend to fall between the paranoid and residual types. The 2 years of intensive treatment and psychosocial support after the first episode are the 'window of opportunity' for functional recovery, and intensive intervention during this period is decisive for long-term prognosis.

Suicide risk: The risk of suicide is high in schizophrenia as a whole, including the undifferentiated type. With a suicide attempt rate of about 20-40% and a completed suicide rate of about 4-10%, regular suicide risk assessment is essential. The first 5 years after the first episode are the period of highest suicide risk.


12. Prevention

Prevention of undifferentiated schizophrenia centers on early detection, shortening of DUP, adequate achievement of remission after the first episode, and relapse prevention.

Early intervention and shortening of DUP: Shortening the duration of untreated psychosis (DUP) has a significant effect on first-episode response rate, achievement of remission, and long-term prognosis alike. Education on early recognition of psychosis in schools, communities, and primary care settings and linkage to early intervention programs (EIP) are key.

Adequate acute-phase treatment: The quality of remission after the first episode determines long-term prognosis. The goal is the most complete remission possible, through antipsychotic drug treatment at an adequate dose and duration combined with psychosocial treatment.

Maintenance therapy to prevent relapse: After remission of the first episode, maintenance antipsychotic drug therapy for at least 1-2 years is recommended. In patients with multiple episodes, long-term or lifelong maintenance therapy is considered. Use of LAI improves adherence and prevents relapse.

Sustaining psychosocial support: Family education, CBT, and linkage to community care contribute to relapse prevention and maintenance of functioning. Treatment of substance use (comorbid cannabis and alcohol use disorders) is important for reducing relapse risk.


13. References

  1. Kahn RS, Sommer IE, Murray RM, et al. Schizophrenia. Nat Rev Dis Primers. 2015;1:15067. DOI: 10.1038/nrdp.2015.67. PMID: 27189524.

  2. Jauhar S, Johnstone M, McKenna PJ. Schizophrenia. Lancet. 2022;399(10323):473-486. DOI: 10.1016/S0140-6736(21)01730-X. PMID: 35093236.

  3. Leucht S, Cipriani A, Spineli L, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013;382(9896):951-962. DOI: 10.1016/S0140-6736(13)60733-3. PMID: 23810019.

  4. Trubetskoy V, Pardiñas AF, Qi T, et al. Mapping genomic loci implicates genes and synaptic biology in schizophrenia. Nature. 2022;604(7906):502-508. DOI: 10.1038/s41586-022-04434-5. PMID: 35396580.

  5. Fusar-Poli P, Bonoldi I, Yung AR, et al. Predicting psychosis: meta-analysis of transition outcomes in individuals at high clinical risk. Arch Gen Psychiatry. 2012;69(3):220-229. DOI: 10.1001/archgenpsychiatry.2011.1472. PMID: 22393215.

  6. Correll CU, Rubio JM, Kane JM. What is the risk-benefit ratio of long-term antipsychotic treatment in people with schizophrenia? World Psychiatry. 2018;17(2):149-160. DOI: 10.1002/wps.20516. PMID: 29745131.

  7. Howes OD, Murray RM. Schizophrenia: an integrated sociodevelopmental-cognitive model. Lancet. 2014;383(9929):1677-1687. DOI: 10.1016/S0140-6736(13)62036-X. PMID: 24315522.

  8. National Institute for Health and Care Excellence (NICE). Psychosis and schizophrenia in adults: prevention and management. NICE guideline CG178. 2014 (updated 2019). Available at: https://www.nice.org.uk/guidance/cg178.

  9. Melle I, Larsen TK, Haahr U, et al. Reducing the duration of untreated first-episode psychosis: effects on clinical presentation. Arch Gen Psychiatry. 2004;61(2):143-150. DOI: 10.1001/archpsyc.61.2.143. PMID: 14757590.

  10. Park SC, Jang EY, Park YC. Prevalence, correlates, and impact of schizophrenia on daily life in Korea: a population-based study. Psychiatry Investig. 2018;15(6):580-586. DOI: 10.30773/pi.2017.11.16. PMID: 29961308.